How do Gitelman syndrome and Bartter syndrome differ in clinical presentation, electrolyte abnormalities, and management?

Distinguishing Gitelman from Bartter Syndrome

The key difference is that Gitelman syndrome presents with hypocalciuria and hypomagnesemia, while Bartter syndrome typically presents with hypercalciuria and earlier, more severe onset (often with polyhydramnios and prematurity). 1, 2

Site of Defect and Pathophysiology

Bartter syndrome results from defective salt reabsorption in the thick ascending limb of Henle's loop (mimicking furosemide effect), affecting proteins NKCC2, ROMK, ClC-Kb, or barttin 1. This leads to:

• Impaired calcium reabsorption → hypercalciuria and nephrocalcinosis
• Loss of medullary osmotic gradient → isosthenuria (inability to concentrate urine)
• Severe polyuria from birth

Gitelman syndrome results from defective salt reabsorption in the distal convoluted tubule (mimicking thiazide effect), affecting the NCC transporter 1, 2. This leads to:

• Enhanced calcium reabsorption → hypocalciuria
• Magnesium wasting → hypomagnesemia
• Preserved urinary concentrating ability

Clinical Presentation

Bartter Syndrome:

• Age of onset: Prenatal to early childhood 1
• Prenatal: Severe polyhydramnios with preterm delivery (median gestational age 29-33 weeks for types 1,2,4) 1
• Neonatal/infantile: Life-threatening dehydration, failure to thrive, severe polyuria
• Type 4a: Associated with sensorineural deafness 1
• Complications: Nephrocalcinosis, chronic kidney disease risk, potential ESRD 1

Gitelman Syndrome:

• Age of onset: Adolescence or adulthood 1, 2
• Presentation: Often incidental finding or mild symptoms
• Symptoms: Tetany, muscle weakness, myalgia, fatigue, vertigo, salt craving 2, 3
• Complications: Chondrocalcinosis (major complication), CKD is exceptional 4, 2
• Note: Type 3 Bartter can be virtually indistinguishable from Gitelman 1

Laboratory Differentiation

Both Share:

• Hypokalemia
• Hypochloremic metabolic alkalosis
• Hyperreninemic hyperaldosteronism
• Normal blood pressure 1, 2

Key Distinguishing Features:

Feature	Bartter	Gitelman
Urinary calcium	High (hypercalciuria)	Low (hypocalciuria)
Serum magnesium	Normal or mild ↓	Markedly low
Nephrocalcinosis	Common	Absent
Urinary concentration	Impaired (isosthenuria)	Preserved
Severity	More severe	Milder

1, 2, 5, 6

Diagnostic Algorithm

1. Confirm renal potassium wasting: Fractional chloride excretion >0.5% 1
2. Exclude secondary causes: Diuretic abuse, laxative abuse, vomiting, primary hyperaldosteronism 1
3. Measure urinary calcium excretion: This is the single most important distinguishing test 5, 6
   • Hypercalciuria → Bartter syndrome
   • Hypocalciuria → Gitelman syndrome
4. Measure serum magnesium:
   • Severe hypomagnesemia → strongly suggests Gitelman
   • Normal/mild hypomagnesemia → suggests Bartter
5. Check for nephrocalcinosis (renal ultrasound): Present in Bartter, absent in Gitelman 1
6. Genetic testing: Confirm diagnosis and identify specific subtype 1
   • Bartter: SLC12A1, KCNJ1, CLCNKB, BSND, CLCNKA, MAGED2
   • Gitelman: SLC12A3

Critical Pitfalls

• 17-23% of Bartter type 3 patients show hypomagnesemia and hypocalciuria, overlapping with Gitelman 7. When uncertain, genetic testing is definitive.
• Pseudo-Bartter/Gitelman syndrome from diuretic abuse, cystic fibrosis, or eating disorders must be excluded 1, 7
• Age alone is unreliable: While Bartter typically presents earlier, some cases present in adolescence/adulthood 1
• Avoid diuretic challenge tests—they are obsolete, dangerous (risk severe volume depletion), and superseded by genetic analysis 1

Management Differences

Bartter syndrome 1, 2:

• Aggressive fluid and electrolyte replacement (sodium chloride, potassium chloride)
• NSAIDs (indomethacin): Mainstay of treatment, especially in infancy, to reduce prostaglandin-mediated polyuria
• Potassium-sparing diuretics (amiloride, spironolactone)
• Magnesium supplementation if needed
• Lifelong intensive monitoring

Gitelman syndrome 2:

• Oral potassium supplementation
• Magnesium supplementation (critical component)
• Liberal salt intake
• Potassium-sparing diuretics for severe hypokalemia (caution: may worsen hypovolemia)
• NSAIDs generally not indicated
• Less intensive monitoring than Bartter

The prognosis is generally better for Gitelman syndrome, with progression to CKD being exceptional, whereas Bartter syndrome carries significant risk of chronic kidney disease and requires more aggressive lifelong management 1, 4, 2.